TFE3 and neoplasm: Various works revisiting series of RCCs with papillary features and studying their molecular and clinical background allowed for discrimination of new tumour entities [21▪▪,22▪,23,24], already incorporated in the WHO classification (e.g. tubulocystic RCC [25], clear cell papillary RCC [26], fumarate-hydratase deficient RCC [27] and TFE3 or TFEB-translocated RCC [28]).